MEA Biosimilars Market Size, by Country (2024–2032)

The MEA Biosimilars Market demonstrated steady regional expansion from *** to ***, with the GCC maintaining its position as the largest and fastest-growing market. GCC values were recorded at USD *** million in ***, are estimated to reach USD *** million in ***, and are projected to reach USD ***.*** million by ***, supported by strong healthcare investments, procurement reforms, and improved biologics accessibility. South Africa was valued at USD *** million in *** and is projected to rise to USD *** million by ***, driven by expanding treatment programs and rising adoption of cost-efficient therapies. Egypt also showed consistent momentum in *** and is projected to reach USD *** million by ***, while Nigeria and the Rest of MEA reflect gradual but meaningful uptake as awareness and infrastructure evolve. Overall, rising affordability initiatives and chronic disease burden continue to shape long-term MEA biosimilars demand.